Thomas A. Lanz

LRRK2 activation in idiopathic Parkinson’s disease

Roberto Di Maio, Eric K. Hoffman, Emily M. Rocha et al. · Science Translational Medicine · 2018 · 603 citations · Full text

Life Sciences, Neurology, Neuroscience +16

MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function

Brooke H. Miller, Zane Zeier, Xi Li et al. · Proceedings of the National Academy of Sciences · 2012 · 308 citations · Full text

Life Sciences, Neuroscience, Psychiatry +15

Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype

Thomas A. Lanz, D.B Carter, Kalpana Merchant · Neurobiology of Disease · 2003 · 225 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder

Thomas A. Lanz, Veronica Reinhart, Mark Sheehan et al. · Translational Psychiatry · 2019 · 188 citations · Full text

Life Sciences, Neuroscience, Psychiatry +14

The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice

Thomas A. Lanz, Carol S. Himes, Giovanni Pallante et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 147 citations

Medicine, Neuroscience, Pharmacology +17